Health topic

Cervical cancer

Cervical cancer

Cervical cancer is the third most prevalent cancer in women around the world, and the fourth highest cause of women's cancer-related deaths.1 In the U.S., the advent of Pap testing has had a tremendous impact on cervical cancer rates—dropping it from the number 1 cause of death in women to number 14.2 Still, 4,220 women in the U.S. die of cervical cancer each year,2 even though it is a theoretically preventable disease. 

The link between cervical cancer and human papillomavirus (HPV) has become clear over the past few decades—today we know that persistent infection with specific types of HPV account for nearly all cases of cervical cancer.2

Because cervical cancer rarely causes overt symptoms in its early stages—when treatment is most effective—screening for HPV infections at the greatest risk of progressing to cervical pre-cancer and cancer is imperative. 

What is HPV?

The most commonly diagnosed sexually transmitted infection in the United States, HPV is most often spread through sexual intercourse, although it can be transmitted via nonpenetrative sexual activity as well.3

HPV is a small, double-stranded DNA virus that affects epithelial cells such as skin and mucous membranes. There are more than 100 HPV genotypes, about 30 of which are sexually transmitted. Most HPV strains are harmless.  However, a handful of high-risk types, however, cause infections that can develop into cervical cancer. 


be confident


cobas®HPV Test

Screen with the cobas® HPV test, the first clinically validated, FDA-approved, CE-IVD marked HPV DNA test for for all cervical screening indications: primary screening, ASC-US triage and co-testing. Screening with HPV DNA can identify women at risk for cervical cancer.  cobas® HPV simultaneously provides pooled results on known high-risk HPV genotypes, and individual results on the two highest-risk genotypes, HPV 16 and HPV 18, giving three results in one from a single sample.

Learn more



CINtec® PLUS Cytology

Triage with CINtec PLUS Cytology - CINtec® PLUS Cytology is the first test that uses dual-biomarker technology to simultaneously detect p16 and Ki-67 to provide a strong indicator of the presence of transforming HPV infections.

Co-expression of p16 and Ki-67 in the same cell is strongly associated with established high-grade disease.

Learn more


CINtec® Histology

Diagnose with CINtec® Histology – Enhances identification of occult cervical lesions that may be missed by H&E or morphologic interpretation alone. The CINtec® Histology test is the only clinically validated test that uses advanced p16 biomarker technology to confirm the presence or absence of cervical lesions due to transforming HPV infections.

Learn more

CINtec® Histology


1. HPV and Cervical Cancer in the World—2007 Report. Vaccine. 2007;25(3): 147-172. Available at: Accessed September 6, 2012.

2. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA: A Cancer Journal for Clinicians. 2012;62(3): 147-172. Available at: Accessed September 6, 2012.

3. Centers for Disease Control and Prevention. Human papillomavirus: Epidemiology and prevention of vaccine-preventable diseases. Available at: Accessed September 7, 2012. 

Found 0 results in